CD30+ peripheral T-cell lymphoma
Haematology · 2021–2021
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| brentuximab vedotin Treatment of patients with previously untreated CD30 positive peripheral T-cell lymphoma (PTCL), non-cutaneous type, in combination with cyclophosphamide,… | Mar 2021 | Recommended with restriction | input received Rare Cancers Australia · Leukaemia Foundation · Lymphoma Group |
Who spoke
Rare Cancers Australia · Leukaemia Foundation · Lymphoma Group
What the PBS pays
$21M in government benefit over 2024–25, across 1,496 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| brentuximab vedotin | $21.4M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.